Neurotoxin-related research: from the laboratory to the clinic.
Iversen
L
L
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, England.
Foster
A C
AC
Hill
R G
RG
Iversen
S D
SD
Kemp
J A
JA
Leeson
P D
PD
Rupniak
N M
NM
Saywell
K
K
Tricklebank
M D
MD
Williams
B J
BJ
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000031:analogs & derivatives / Q000627:therapeutic use; D020267:MPTP Poisoning; D051379:Mice; D009420:Nervous System / Q000187:drug effects; D009498:Neurotoxins; D010078:Oxazines / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D011355:Prodrugs / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000502:physiology; D017448:Receptors, Dopamine D2; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology; D012453:Saimiri
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D009498:Neurotoxins; D010078:Oxazines; D011355:Prodrugs; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D016194:Receptors, N-Methyl-D-Aspartate; C061031:L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine; C042631:naxagolide; D007980:Levodopa